Hiroki Hidejima
Direttore/Membro del Consiglio presso METAREAL CORPORATION
Patrimonio netto: 1 M $ in data 30/04/2024
Posizioni attive di Hiroki Hidejima
Società | Posizione | Inizio | Fine |
---|---|---|---|
METAREAL CORPORATION | Direttore/Membro del Consiglio | 01/04/2004 | - |
J & I YK | Direttore/Membro del Consiglio | 01/02/2004 | - |
YES-fm KK | Comptroller/Controller/Auditor | 01/03/2005 | - |
C.H.C. SYSTEM Co., Ltd. | Direttore/Membro del Consiglio | 01/05/2005 | - |
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Direttore/Membro del Consiglio | 01/07/2010 | - |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Direttore/Membro del Consiglio | 01/06/2014 | - |
THANN Natural KK | Direttore/Membro del Consiglio | 01/06/2012 | - |
Development Association For Youthleaders | Direttore/Membro del Consiglio | 01/03/2004 | - |
Storia della carriera di Hiroki Hidejima
Formazione di Hiroki Hidejima
Kobe University Graduate School of Business Administration | Undergraduate Degree |
Statistiche
Distribuzione geografica
Giappone | 9 |
Germania | 2 |
Posizioni
Director/Board Member | 7 |
Undergraduate Degree | 1 |
Comptroller/Controller/Auditor | 1 |
Settori
Technology Services | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
METAREAL CORPORATION | Technology Services |
Aziende private | 7 |
---|---|
J & I YK | |
YES-fm KK | |
C.H.C. SYSTEM Co., Ltd. | |
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Commercial Services |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Health Technology |
THANN Natural KK | |
Development Association For Youthleaders |
- Borsa valori
- Insiders
- Hiroki Hidejima
- Esperienza